TY - JOUR
T1 - Novel biomarkers for prognosticating diabetic kidney disease progression
AU - Swaminathan, Shilna Muttickal
AU - Rao, Indu Ramachandra
AU - Shenoy, Srinivas Vinayak
AU - Prabhu, Attur Ravindra
AU - Mohan, Pooja Basthi
AU - Rangaswamy, Dharshan
AU - Bhojaraja, Mohan V.
AU - Nagri, Shivashankara Kaniyoor
AU - Nagaraju, Shankar Prasad
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022
Y1 - 2022
N2 - The global burden of diabetic kidney disease (DKD) is escalating, and it remains as a predominant cause of the end-stage renal disease (ESRD). DKD is associated with increased cardiovascular disease and morbidity in all types of diabetes. Prediction of progression with albuminuria and eGFR is challenging in DKD, especially in non-proteinuric DKD patients. The pathogenesis of DKD is multifactorial characterized by injury to all components of the nephron, whereas albuminuria is an indicator of only glomerular injury. The limits in the diagnostic and prognostic value of urine albumin demonstrate the need for alternative and clinically significant early biomarkers, allowing more targeted and effective diabetic treatment, to reduce the burden of DKD and ESRD. Identification of biomarkers, based on multifactorial pathogenesis of DKD can be the crucial paradigm in the treatment algorithm of DKD patients. This review focuses on the potential biomarkers linked to DKD pathogenesis, particularly with the hope of broadening the diagnostic window to identify patients with different stages of DKD progression.
AB - The global burden of diabetic kidney disease (DKD) is escalating, and it remains as a predominant cause of the end-stage renal disease (ESRD). DKD is associated with increased cardiovascular disease and morbidity in all types of diabetes. Prediction of progression with albuminuria and eGFR is challenging in DKD, especially in non-proteinuric DKD patients. The pathogenesis of DKD is multifactorial characterized by injury to all components of the nephron, whereas albuminuria is an indicator of only glomerular injury. The limits in the diagnostic and prognostic value of urine albumin demonstrate the need for alternative and clinically significant early biomarkers, allowing more targeted and effective diabetic treatment, to reduce the burden of DKD and ESRD. Identification of biomarkers, based on multifactorial pathogenesis of DKD can be the crucial paradigm in the treatment algorithm of DKD patients. This review focuses on the potential biomarkers linked to DKD pathogenesis, particularly with the hope of broadening the diagnostic window to identify patients with different stages of DKD progression.
UR - http://www.scopus.com/inward/record.url?scp=85140320982&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140320982&partnerID=8YFLogxK
U2 - 10.1007/s11255-022-03354-7
DO - 10.1007/s11255-022-03354-7
M3 - Review article
AN - SCOPUS:85140320982
SN - 0301-1623
VL - 55
SP - 913
EP - 928
JO - International Urology and Nephrology
JF - International Urology and Nephrology
IS - 4
ER -
